Through this exciting partnership and adoption of breakthrough technology, we are well-positioned to drive the creation of more sustainable and effective products that meet the demands of our consumers and fulfils our duty of care for the planet,” says L’Oréal Groupe’s Guive Balooch on the firm’s expanded partnership with Debut Biotechnology. More cosmetics news in brief.
San Diego-based Debut Biotechnology, Inc. is expanding its agreement with L’Oréal SA to develop more than a dozen “vital, bio-identical” ingredients that will replace conventionally sourced ingredients currently used in L’Oréal’s global beauty and personal-care brands across skin, hair, color cosmetics and fragrances, the firm announced on 2 July.
The company inked an agreement last summer with L’Oréal to develop “the next generation of high-performing active ingredients” for beauty...
Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
